Medytox announced on the 10th that its preliminary consolidated third-quarter operating profit was tallied at KRW 15.531 billion.

The operating profit represents a 74.5% increase from the same period last year and a 225.9% increase from the previous quarter. Meanwhile, revenue for the same period fell 2.8% year-on-year and 13.7% quarter-on-quarter to KRW 59.314 billion.

Profit from continuing operations before income tax expenses rose 76.6% year-on-year and 222.6% quarter-on-quarter to KRW 13.741 billion. Net income climbed 61.4% year-on-year and 271.4% quarter-on-quarter to KRW 11.616 billion. Net income attributable to owners of the parent company increased 55.7% year-on-year and 272.4% quarter-on-quarter to KRW 11.572 billion.

■ Cumulative Performance for Q1–Q3 Cumulative revenue for the first three quarters of this year rose 1.1% year-on-year to KRW 188.705 billion, while cumulative operating profit grew 33.7% to KRW 27.668 billion.

Cumulative profit from continuing operations before income tax expenses for the same period increased 34.7% year-on-year to KRW 27.702 billion. Cumulative net income grew 20.9% to KRW 22.623 billion, and net income attributable to owners of the parent company rose 14.6% to KRW 22.475 billion.

■ Notes on Preliminary Results Medytox stated that these results are preliminary consolidated figures prepared in accordance with Korean International Financial Reporting Standards (K-IFRS). The company explained that the figures were compiled before the external auditor's review was completed, and that the results may be revised during the audit process.